HK StockDetailed Quotes

Provided by TTMF Limited

BIOKINUnlisted

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:- -

Open:- -

Low:- -

Close:- -

52wk High:- -

52wk Low:- -

Shares:421.51M

HK Float Shares:421.51M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:-14.94%

ROA:-5.41%

PB:0.00

PE(LYR):- -

PS:0.00

1

Offering

Nov 07

2

Closed

Nov 12 09:30

3

IPO Result

Nov 13

4

Grey Mkt.

Dec 31 16:15 - 18:30

5

Listing

Nov 17

Overview Company News Filings

BIOKIN's EGFR×HER3 Bispecific ADC Iza-bren Meets Primary Endpoints in Phase III Trial for Advanced Triple-Negative Breast Cancer

Biokin Faces Dual Pressure from Earnings and Stock Performance

BIOKIN (688506.SH): Iza-bren (EGFR×HER3 Bispecific ADC) for Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Included in Priority Review Program

Over 160 Billion Yuan in Lock-Up Shares to Flood Market Next Week, Three Stocks Face Over 10 Billion Yuan in Lifting Restrictions

Sichuan Biokin Pharmaceutical (688506.SH) Subsidiary Receives $250 Million Milestone Payment from Bristol-Myers Squibb for Iza-Bren Project

Sichuan Biokin Pharmaceutical Gets Acceptance for Cancer Drug Application

MT Newswires Live

Sichuan Biokin Pharmaceutical Seeks Credit Support from Bank of China Sichuan Branch

MT Newswires Live

Sichuan Biokin Pharmaceutical (688506.SH): Iza-bren Meets Dual Primary Endpoints in Phase III Trial for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Biokin's Hong Kong IPO Faces Sudden Setback

Rare Move: BIOKIN (2615.HK) Delays IPO Just Before Closing—Why?

Sichuan Biokin Pharmaceutical Postpones Hong Kong IPO

MT Newswires Live

Sichuan Biokin Pharmaceutical (2615) Announces Postponement of Global Offering and Listing

Bulletin Express

Hong Kong Stock Investment Log | November 12, 2025

BIOKIN (02615) Debuts on HKEX with Blockbuster ADC Drug Potential Exceeding $20 Billion

Sichuan Biokin Launches Hong Kong IPO; Eyes Broader Mainland Investor Reach Via Stock Connect

Benzinga_recent_news

BRIEF-Sichuan Biokin Pharmaceutical Announces Global Offering

Sichuan Biokin Pharmaceutical (02615) Opens IPO Subscription from Nov 7 to Nov 12, Expected Listing on Nov 17

Sichuan Biokin Pharmaceutical (688506.SH): T-Bren (HER2 ADC) for HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Included in Breakthrough Therapy List

Sichuan Biokin Reports Q3 Milestone Revenue of $250 Million, Soaring 1625.08% Year-On-Year

Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) Reports Q3 Earnings, Net Loss of 495 Million Yuan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02615/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02615","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"BIOKIN","latestPrice":0,"timestamp":1771833600000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"To be listed","change":0,"latestTime":"02-23 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1771810200000,1771819200000],[1771822800000,1771833600000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"Sichuan Biokin Pharmaceutical Co.,Ltd.","latestPrice":287,"timestamp":1770966000000,"preClose":289.4,"halted":0,"volume":1025500,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","floatShares":421508117,"roa":"-5.41%","roe":"-14.94%","lyrEps":0,"shares":421508117,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.204,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02615\",,undefined,":{"id":9063,"type":"COMMON","ipoName":"02615-IPO","symbol":"02615","companyName":"BIOKIN","market":"HK","currency":"HKD","status":"CANCELLED","underwriter":"Goldman Sachs (Asia) L.L.C.","lotSize":100,"minQty":100,"expectedOfferingSize":8634300,"openingDate":1762479000000,"closingDate":1762911000000,"commonClosingDate":1762911000000,"allotmentDate":1762963200000,"listDate":1763308800000,"marginable":true,"latestPrice":389,"minPrice":347.5,"maxPrice":389,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700013.pdf","allowedQuantities":[100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700],"recommend":false,"isHint":false,"interestStartDate":1762876800000,"interestEndDate":1762876800000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1763108100000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[],"latestClosingDate":1771844706886,"subscribedFinanceRatio":19.93,"subscribedRatio":19.93,"forecastRatio":24.31,"raiseMoney":335900000,"totalMargin":6694640000,"quoteInfoUpdatedAt":1771814778245,"prospectusUpdatedAt":1762928848000,"forecastMarketValue":155220364085.25,"minForecastMarketValue":146474070657.5,"maxForecastMarketValue":163966657513,"sharesOutstanding":421508117,"business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"tradable":false,"showClawback":false},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02615\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1192115369","title":"BIOKIN's EGFR×HER3 Bispecific ADC Iza-bren Meets Primary Endpoints in Phase III Trial for Advanced Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1192115369","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192115369?lang=en_us&edition=fundamental","pubTime":"2026-02-23 17:00","pubTimestamp":1771837219,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that an interim analysis of the Phase III clinical trial for iza-bren, an EGFR×HER3 bispecific antibody-drug conjugate (ADC), in patients...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["91194","III","BK4080","BK4231","688506","ADC","BK0239","BK4134","02615"],"gpt_icon":0},{"id":"1172970142","title":"Biokin Faces Dual Pressure from Earnings and Stock Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=1172970142","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172970142?lang=en_us&edition=fundamental","pubTime":"2026-02-09 14:52","pubTimestamp":1770619921,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical is experiencing a significant downturn in its traditional pharmaceutical operations while continuing to invest heavily in innovative drug development. The company is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615","91194","688506","BK0239"],"gpt_icon":0},{"id":"1162586133","title":"BIOKIN (688506.SH): Iza-bren (EGFR×HER3 Bispecific ADC) for Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Included in Priority Review Program","url":"https://stock-news.laohu8.com/highlight/detail?id=1162586133","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162586133?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:58","pubTimestamp":1767689914,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) announced that its self-developed, first-in-class, new-concept bispecific ADC (Antibody-Drug Conjugate) iza-bren for injection has been included in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615","BK4231","BK0239","BK4080","91194","ADC","688506"],"gpt_icon":0},{"id":"1180985873","title":"Over 160 Billion Yuan in Lock-Up Shares to Flood Market Next Week, Three Stocks Face Over 10 Billion Yuan in Lifting Restrictions","url":"https://stock-news.laohu8.com/highlight/detail?id=1180985873","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180985873?lang=en_us&edition=fundamental","pubTime":"2026-01-04 21:41","pubTimestamp":1767534096,"startTime":"0","endTime":"0","summary":"According to Wind data, during the week of January 5th to 9th, a total of 37 A-share companies will see their restricted shares become eligible for trading, with the combined lifted market value...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615"],"gpt_icon":0},{"id":"1169803746","title":"Sichuan Biokin Pharmaceutical (688506.SH) Subsidiary Receives $250 Million Milestone Payment from Bristol-Myers Squibb for Iza-Bren Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1169803746","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169803746?lang=en_us&edition=fundamental","pubTime":"2025-11-30 17:00","pubTimestamp":1764493215,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its wholly-owned subsidiary, SystImmune, recently received a $250 million milestone payment from Bristol-Myers Squibb (BMY)....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU1670711123.USD","LU1868836757.USD","BK4581","LU0882574055.USD","LU1868837136.USD","02615","LU0096364046.USD","LU0321505439.SGD","LU1032466523.USD","IE00BJJMRZ35.SGD","BK4534","LU2360032135.SGD","LU1571399168.USD","BK0239","LU1291159041.SGD","LU1430594728.SGD","LU0306807586.USD","LU0114720955.EUR","LU0061475181.USD","IE0002141913.USD","LU1868836914.USD","LU1093756325.SGD","LU0985481810.HKD","LU1670710588.SGD","LU1718418525.SGD","LU1323610961.USD","LU1989771016.USD","BK4007","LU2242652126.USD","BMY","IE0009355771.USD","IE00B2B36J28.USD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU0456855351.SGD","IE00BSNM7G36.USD","LU2125154778.USD","LU0868494617.USD","688506","LU1074936037.SGD","LU1670710661.SGD","LU0267386448.USD","BK4532","LU0321505868.SGD","LU1868837300.USD","91194","LU1585245621.USD","LU1670711040.USD","LU1868836591.USD","LU2125154935.USD","BK4585","LU1261432733.SGD","LU0237698245.USD","LU0225771236.USD","LU0306806265.USD","BK4559","LU2133065610.SGD","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4588","LU0225284248.USD"],"gpt_icon":0},{"id":"2585437299","title":"Sichuan Biokin Pharmaceutical Gets Acceptance for Cancer Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437299","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585437299?lang=en_us&edition=fundamental","pubTime":"2025-11-24 11:52","pubTimestamp":1763956368,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  said its new drug application for innovative cancer treatment iza-bren has been accepted by China's medical products administrator.The drug is intended for locally advanced or metastatic nasopharyngeal carcinoma that failed prior treatments, according to a Monday filing with the Shanghai bourse.Shares of the pharmaceutical company were up 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02615","688506","BK0239"],"gpt_icon":0},{"id":"2584183711","title":"Sichuan Biokin Pharmaceutical Seeks Credit Support from Bank of China Sichuan Branch","url":"https://stock-news.laohu8.com/highlight/detail?id=2584183711","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584183711?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:33","pubTimestamp":1763624012,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  sought total credit support from the Bank of China  Sichuan branch for up to 8 billion yuan, according to a Thursday filing with the Shanghai bourse.Under their strategic cooperation agreement, the two parties will cooperate to improve foreign capital market operations, among others, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2097828714.EUR","IE00BWDBJ730.SGD","LU1634259391.SGD","LU0651946864.USD","BK0015","03988","BK0028","IE00BQJZWZ67.USD","LU0651947912.USD","SG9999006597.SGD","LU0588546209.SGD","LU1497733631.SGD","BK1231","BK0183","688506","LU1051768304.USD","LU1634259557.SGD","BK0278","LU1497734951.SGD","LU1522347837.USD","LU1515016050.SGD","601988","BK0239","LU0307460666.USD","LU1497733557.USD","03143","LU0293314216.USD","LU1282651121.HKD","SG9999001093.SGD","IE00B19Z5X02.USD","LU1048588211.SGD","LU2097828474.EUR","BK0012","BK1521","BK0188","LU1282651048.USD","LU0348805143.USD","LU2097828631.EUR","02615","BK1560","LU1051769294.HKD","LU0072462343.USD","LU2097828557.USD","LU2097828805.USD","LU1224444064.USD"],"gpt_icon":0},{"id":"1144162041","title":"Sichuan Biokin Pharmaceutical (688506.SH): Iza-bren Meets Dual Primary Endpoints in Phase III Trial for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1144162041","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144162041?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:28","pubTimestamp":1763425696,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its self-developed, first-in-class, novel-concept EGFR×HER3 bispecific antibody-drug conjugate (iza-bren), currently the only one in...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["91194","BK4134","III","BK0239","02615","688506"],"gpt_icon":0},{"id":"1144480938","title":"Biokin's Hong Kong IPO Faces Sudden Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=1144480938","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144480938?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:00","pubTimestamp":1762959655,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin, 688506.SH), which had passed the Hong Kong Stock Exchange (HKEX) hearing in late October 2025, announced an unexpected delay in its H-share global...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","91194","02615","HEXmain","BK0239"],"gpt_icon":0},{"id":"1174274910","title":"Rare Move: BIOKIN (2615.HK) Delays IPO Just Before Closing—Why?","url":"https://stock-news.laohu8.com/highlight/detail?id=1174274910","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174274910?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:11","pubTimestamp":1762938661,"startTime":"0","endTime":"0","summary":"The red-hot Hong Kong IPO market witnessed an unusual case this year as Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) (new listing code: 2615.HK), already listed on the A-share market, abruptly...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","91194","02615","BK0239"],"gpt_icon":0},{"id":"2582934387","title":"Sichuan Biokin Pharmaceutical Postpones Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2582934387","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582934387?lang=en_us&edition=fundamental","pubTime":"2025-11-12 11:46","pubTimestamp":1762919182,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  has decided to postpone its planned Hong Kong initial public offering, scheduled for Nov. 17, citing prevailing market conditions, according to a Wednesday bourse filing.The Chinese integrated pharmaceutical firm said it will not proceed with the offering as outlined in its November 7 prospectus, and the international and Hong Kong underwriting agreements will not take effect.Application monies for the Hong Kong public offering will be refunded in full without interest starting November 17, the filing said.Biokin added that the postponement does not affect its current operations while reassessing a new timetable.The firm launched its listing last week, aiming to raise up to HK$3.36 billion from the offering.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688506","BK0239","02615"],"gpt_icon":0},{"id":"1160335775","title":"Sichuan Biokin Pharmaceutical (2615) Announces Postponement of Global Offering and Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1160335775","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160335775?lang=en_us&edition=fundamental","pubTime":"2025-11-12 11:21","pubTimestamp":1762917695,"startTime":"0","endTime":"0","summary":"Hong Kong Exchanges and Clearing Limited, the Stock Exchange of Hong Kong Limited, and Hong Kong Securities Clearing Company Limited disclaim all responsibility for the announcement by Sichuan Biokin...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615"],"gpt_icon":0},{"id":"1107367828","title":"Hong Kong Stock Investment Log | November 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1107367828","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107367828?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:02","pubTimestamp":1762876933,"startTime":"0","endTime":"0","summary":"The investment log for Hong Kong-listed companies on November 12, 2025, is as follows: **New Share Offerings**   - BIOKIN (Ongoing)   - CNGR (Ongoing) **Earnings Announcements**   - Vietnam...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02515","02579","02615","BK1148"],"gpt_icon":0},{"id":"1164256955","title":"BIOKIN (02615) Debuts on HKEX with Blockbuster ADC Drug Potential Exceeding $20 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1164256955","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164256955?lang=en_us&edition=fundamental","pubTime":"2025-11-11 09:04","pubTimestamp":1762823072,"startTime":"0","endTime":"0","summary":"Technology-driven innovation, surging demand, and policy support have been the three key drivers behind the sustained market enthusiasm for ADC drugs in recent years. For the Hong Kong stock market,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","91194","02615","688506"],"gpt_icon":0},{"id":"2581881746","title":"Sichuan Biokin Launches Hong Kong IPO; Eyes Broader Mainland Investor Reach Via Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881746","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881746?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:51","pubTimestamp":1762527060,"startTime":"0","endTime":"0","summary":"Biopharmaceutical companySichuan Biokin Pharmaceuticallaunchedits Hong Kong IPO on Friday, aiming to raise up to HK$3.36 billion  by selling 8.63 million shares for between HK$347.50 and HK$389 each. Subscriptions will close on Nov. 12, with a Hong Kong trading debut set for Nov. 17.The company is already listed on China's domestic A-share market in Shanghai, meaning it's eligible for inclusion in the Hong Kong Stock Connect program that could make its newly listed shares available to Mainland China-based investors as early as the day of their trading debut. The program allows investors on the Chinese Mainland and in Hong Kong to trade stocks in each other's markets.The developer of innovative large-molecule oncology therapies, including antibody-drug conjugates , likened to \"biological missiles\" against cancer, has been a strong performer on Shanghai's Nasdaq-style STAR Market since it went public there in early 2023. Its stock has risen more than tenfold since that time.Benzinga Disc","market":"us","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/25/11/48720159/sichuan-biokin-launches-hong-kong-ipo-eyes-broader-mainland-investor-reach-via-stock-connect","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/25/11/48720159/sichuan-biokin-launches-hong-kong-ipo-eyes-broader-mainland-investor-reach-via-stock-connect","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["02615"],"gpt_icon":0},{"id":"2581233560","title":"BRIEF-Sichuan Biokin Pharmaceutical Announces Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2581233560","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581233560?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:22","pubTimestamp":1762478529,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Biokin Pharmaceutical Announces Global OfferingNov 7 (Reuters) - Sichuan Biokin Pharmaceutical 2615.HKNUMBER OF OFFER SHARES UNDER GLOBAL OFFERING 8.6 MILLION H SHARESMAXIMUM OFFER PRICE HK$389.00 PER H SHARE UNDER GLOBAL OFFERING ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WI2AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615"],"gpt_icon":0},{"id":"1153696444","title":"Sichuan Biokin Pharmaceutical (02615) Opens IPO Subscription from Nov 7 to Nov 12, Expected Listing on Nov 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1153696444","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153696444?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:56","pubTimestamp":1762469789,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical (02615) has announced its initial public offering (IPO) subscription period from November 7 to November 12, 2025. The company plans to issue 8.6343 million shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","BK0239","02615"],"gpt_icon":0},{"id":"1100060903","title":"Sichuan Biokin Pharmaceutical (688506.SH): T-Bren (HER2 ADC) for HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Included in Breakthrough Therapy List","url":"https://stock-news.laohu8.com/highlight/detail?id=1100060903","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100060903?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:02","pubTimestamp":1762254148,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its self-developed innovative biologic drug T-Bren (HER2 ADC), a HER2-targeting novel ADC with Best-in-Class potential, has...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615","ADC","BK4080","688506","BK0239","BK4231"],"gpt_icon":0},{"id":"1111458873","title":"Sichuan Biokin Reports Q3 Milestone Revenue of $250 Million, Soaring 1625.08% Year-On-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1111458873","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111458873?lang=en_us&edition=fundamental","pubTime":"2025-10-26 19:14","pubTimestamp":1761477267,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. has released its financial report for the third quarter of 2025, revealing a quarterly revenue of 1.895 billion yuan, a remarkable increase of 1625.08%...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","02615","688506"],"gpt_icon":0},{"id":"1119999206","title":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) Reports Q3 Earnings, Net Loss of 495 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1119999206","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119999206?lang=en_us&edition=fundamental","pubTime":"2025-10-26 16:06","pubTimestamp":1761465967,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has released its third-quarter report for 2025, revealing that the company generated revenue of 2.066 billion yuan in the first three quarters,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","BK0239","02615"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}